少関節型乾癬性関節炎患者における インターロイキン-17抑制
Rheumatol Ther. 2023;10(4):849-860 doi: 10.1007/s40744-023-00548-y
Secukinumab reduced disease activity across a range of outcome measures by week 12, with sustained responses through 52 weeks.
Ogdie, et al. evaluated the clinical efficacy and safety of secukinumab in patients with oligoarticular PsA using pooled data from the FUTURE 2–5and MAXIMISE trials.
